{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:15:55Z","timestamp":1788196555554,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2024 Hebei Province Medical Science Research Project Plan","award":["20240422"],"award-info":[{"award-number":["20240422"]}]},{"name":"2025 Hebei Province Traditional Chinese Medicine Scientific Research Project Plan","award":["2025027"],"award-info":[{"award-number":["2025027"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,12]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Ceftazidime-avibactam is widely used to treat infections caused by carbapenem-resistant Gram-negative bacteria. Although it is generally considered safe, cases of severe hypokalemia associated with its use have rarely been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>\n                      A 74-year-old man with severe pneumonia and acute cerebral infarction was treated with ceftazidime-avibactam after sputum culture and nucleic acid testing identified multidrug-resistant\n                      <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      . Soon after initiation of therapy, he developed persistent and refractory hypokalemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Drug-induced severe hypokalemia secondary to ceftazidime-avibactam was diagnosed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Antimicrobial therapy was continued, and the patient received oral spironolactone and nasogastric potassium chloride. Because of persistent hypokalemia and the development of acute kidney injury, the dose of ceftazidime-avibactam was reduced by half. After dose adjustment and continued potassium supplementation, serum potassium levels gradually stabilized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome:<\/jats:title>\n                    <jats:p>The patient\u2019s condition worsened due to multiple organ failure and septic shock. At the request of his family, he was discharged against medical advice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case suggests that avibactam may promote potassium loss by enhancing renal tubular secretion and increasing luminal electronegativity. Clinicians should be aware of this potential adverse effect, particularly in elderly patients or those with renal dysfunction. Close monitoring of serum and urinary potassium levels, along with early correction of abnormalities, is strongly recommended during treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049288","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:02:28Z","timestamp":1781600548000},"page":"e49288","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Severe hypokalemia induced by ceftazidime-avibactam: Case report"],"prefix":"10.1097","volume":"105","author":[{"given":"Ye","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Rehabilitation, Hebei General Hospital, Shijiazhuang, China"},{"name":"Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Hebei General Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9718-6941","authenticated-orcid":false,"given":"Yang","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hebei General Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hebei General Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Hebei General Hospital, Shijiazhuang, China"},{"name":"Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Hebei General Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6192-0287","authenticated-orcid":false,"given":"Yu","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Hebei General Hospital, Shijiazhuang, China"},{"name":"Hebei Provincial Key Laboratory of Cerebral Networks and Cognitive Disorders, Hebei General Hospital, Shijiazhuang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260831","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections.","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13756-025-01518-5","article-title":"Global trends of ceftazidime-avibactam resistance in gram-negative bacteria: systematic review and meta-analysis.","volume":"14","author":"Wang","year":"2025","journal-title":"Antimicrob Resist Infect Control"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.2147\/IDR.S435882","article-title":"Clinical efficacy and safety evaluation of ceftazidime-avibactam in the treatment of Klebsiella pneumoniae infection: a retrospective analysis from a hospital in China.","volume":"16","author":"Xu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jiph.2022.02.003","article-title":"Analysis of the clinical application of ceftazidime-avibactam in China.","volume":"15","author":"Wang","year":"2022","journal-title":"J Infect Public Health"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","article-title":"Safety evaluation of ceftazidime\/avibactam based on FAERS database.","volume":"52","author":"Zhang","year":"2024","journal-title":"Infection"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jcph.2420","article-title":"A real-world pharmacovigilance study of ceftazidime\/avibactam: data mining of the food and drug administration adverse event reporting system database.","volume":"64","author":"Yao","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1111\/bcp.15844","article-title":"Ceftazidime\/avibactam-induced severe neutropenia: a case report.","volume":"89","author":"Wu","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10096-020-04149-3","article-title":"Serious adverse events with novel beta-lactam\/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.","volume":"40","author":"Gatti","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"3000605241253447","DOI":"10.1177\/03000605241253447","article-title":"Beta-lactam-associated hypokalemia.","volume":"52","author":"Jansen","year":"2024","journal-title":"J Int Med Res"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/antibiotics12020240","article-title":"Electrolyte disorders associated with piperacillin\/tazobactam: a pharmacovigilance study using the FAERS database.","volume":"12","author":"Seo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"35517","DOI":"10.1038\/s41598-025-19484-8","article-title":"Ampicillin sulbactam impacts serum potassium level comparable to piperacillin tazobactam.","volume":"15","author":"Tashiro","year":"2025","journal-title":"Sci Rep"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"105891","DOI":"10.1016\/j.ijantimicag.2020.105891","article-title":"Ceftolozane\/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review of its efficacy and safety for off-label indications.","volume":"55","author":"Maraolo","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions.","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/dmd.113.055335","article-title":"Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential.","volume":"42","author":"Vishwanathan","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"R15-20260831","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/bcp.15236","article-title":"Hypokalaemia in patients treated with intravenous flucloxacillin: incidence and risk factors.","volume":"88","author":"Leegwater","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"703","DOI":"10.23876\/j.krcp.24.012","article-title":"Pathological and functional significance of aging mouse kidneys: clinical implications to reduce the risk of hyper- or hypokalemia in the elderly.","volume":"43","author":"Kazama","year":"2024","journal-title":"Kidney Res Clin Pract"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"800055","DOI":"10.3389\/fphys.2022.800055","article-title":"Dissecting the effects of aldosterone and hypokalemia on the epithelial Na(+) channel and the NaCl cotransporter.","volume":"13","author":"Kristensen","year":"2022","journal-title":"Front Physiol"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1113\/JP284041","article-title":"Dietary sodium alters aldosterone\u2019s effect on renal sodium transporter expression and distal convoluted tubule remodelling.","volume":"602","author":"Mutchler","year":"2024","journal-title":"J Physiol"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/jrms.jrms_277_24","article-title":"The association of hypokalemia with meropenem administration: a case report and literature review.","volume":"29","author":"Timamy","year":"2024","journal-title":"J Res Med Sci"},{"key":"R20-20260831","first-page":"Od05","article-title":"Meropenem induced hypokalemia.","volume":"11","author":"Anuhya","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"R21-20260831","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eimc.2018.06.013","article-title":"Hypokalaemia probably associated with ceftolozane\/tazobactam treatment: three case reports.","volume":"37","author":"Toro Blanch","year":"2019","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"R22-20260831","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1071\/SH19069","article-title":"Severe acute hypokalaemia associated with piperacillin\/tazobactam in an HIV-infected patient under antiretroviral therapy with tenofovir alafenamide: case report and literature review.","volume":"17","author":"Tai","year":"2020","journal-title":"Sex Health"},{"key":"R23-20260831","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/ijp.IJP_532_19","article-title":"A rare case of cephalexin-induced acute interstitial nephritis with hypokalemic periodic paralysis.","volume":"52","author":"Kumar","year":"2020","journal-title":"Indian J Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:00:17Z","timestamp":1788195617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":23,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049288","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2026-03-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}